Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

VBP

- PMLiVE

Budget 2018: UK life sciences sector delivers its verdict

UK Chancellor Philip Hammond delivered a budget that was broadly pro-business but contained mixed news for the life sciences industry, according to two industry bodies.The headline news of an additional...

- PMLiVE

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

Both companies made same error in modelling, says NICE

Pharma: in search of the sustainable ‘win win’ with the NHS

Fiona Bride on how Novartis is responding to new models of care

- PMLiVE

Hancock’s ‘Tech Revolution’ for NHS to be limited by budgets

Vision for a tech-driven NHS unveiled, but is there money to fund it?

- PMLiVE

Cancer care – the power of new technologies

With patient numbers set to soar, how can we make a difference?

- PMLiVE

Hancock says UK genome service is now ‘rolling out’

Health secretary also announces a £240m social care boost

- PMLiVE

UK pharma to work with innovation network on NHS uptake

The five year deal covers AI, genomics, personalised medicine and more

- PMLiVE

Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma

Proactive adjuvant treatment could extend melanoma patient lives

- PMLiVE

Controversy grows around GP at Hand service after minister’s endorsement

Hancock says service should be rolled out across England

Roche Basel Switzerland

Dismay as NICE rejects Roche’s MS drug Ocrevus

Treatment deemed too costly to treat primary progressive MS

- PMLiVE

NICE turns down Opdivo for adjuvant melanoma therapy

BMS drug currently only licensed treatment in this setting

- PMLiVE

Outdated health service IT ‘cost lives’ says health secretary

Matt Hancock outlines plan for a “tech-driven” NHS

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links